Aug
3

More on drugs in workers comp

Drugs account for over one-eighth of workers compensation medical expenses, and that number continues to increase. The data from NCCI’s latest research paper on workers compensation drug costs is consistent with the findings of my firm’s research, and provides additional detail on the specific drugs that account for the majority of dollars spent.
NCCI’s report includes results up to 2003; while there have been several significant changes since then (the disappearance of most of the COX-2s, patent expiration on Oxycontin, and the explosive growth of Actiq), the report’s year-over-year trend data is sobering.
Of note, experience indicates that the most sophisticated payers are holding increases in the 2-5% range through the use of clinical management programs, data mining, adjuster training, strong EDI connections, and intelligent third party biller strategies.
Their less-sophisticated colleagues are at the other end of the spectrum, experiencing 15% and higher annnual inflation rates.
What does this mean for you?
If you aren’t working hard on this, you may want to get started.


Jul
23

Drugs in Workers Comp – Survey Report

My firm’s third annual survey of prescription drug management in workers comp has been completed, and here are a few of the findings.
1. Drug costs increased slightly more than 10% last year, a “decrease in the rate of increase” over prior years.
2. Respondents, which ranged from small regional payers to the largest national insurers, are getting more sophisticated about drugs and drug management. This is evidenced by respondents’ increasing focus on clinical management programs; access to more and better data about their programs and results thereof; and greater attention on utilization vs. price.
3. Third party billers continue to frustrate payers, with almost 90% viewing TPBs as problematic. Concerns included reduced data quality, increased administrative problems and workload, and increased costs.
4. Drug repackaging is also high on respondents’ lists of problems, with particular emphasis on the California situation and physician dispensing.
A copy of the survey report can be obtained by emailing me at jpaduda@healthstrategyassoc.com


Jun
21

Big pharma v big government

Prices on branded drugs increased 3.9% in Q1 2006(registration required), the largest increase in six years. Coincidentally, the Medicare Part D drug coverage program went into effect 1/1/2006. Part D has resulted in somewhere around ten million new customers for insurers, who will now pay 4.7% more for Lipitor and 13.3% more for Ambien.
In terms of dollars, AARP calculates the average senior’s costs will increase by almost $20 per month, as the Part D providers are passing the cost increases along to their subscribers.
There has been the usual rash of outraged protests from various mouthpieces for big pharma, all of which are either disingenuous, outrageously self-serving, misleading, or poor attempts at deflecting blame towards insurers et al.
So what happens when pharma decides to increase prices?
Well, the mass media starts looking at what the Veterans Administration pays for drugs. Compared to the VA, the only federal entity allowed to negotiate prices, Part D prices are now 46% higher on average.
Here are a couple examples, quoted from the Families USA report.
“For Zocor (20 mg), the lowest VA price for a year’s treatment was $127.44, while the lowest Part D plan price was $1,275.36, a difference of $1,147.92 or 901 percent.
For Fosamax (70 mg), the lowest VA price for a year’s treatment was $265.32, while the lowest Part D plan price was $727.92, a difference of $462.60 or 174 percent.”
So here we have big government, in the form of the VA, delivering prices that are about half of what private industry can obtain. While that’s kind of interesting, it gets way more than “kind of” interesting when you consider that Part D has added $8 trillion to the nation’s long term debt. That’s a quarter of the entire Medicare deficit
Tell me again how privatizing health care for seniors is a good deal for taxpayers, seniors, and the country?


Jun
9

URAC is getting into drugs

URAC, the national body that is the self-described “leader in promoting health care quality through its accreditation and certification” of managed care firms, processes, and programs, is getting into the PBM certification business. According to a recent press release, URAC has formed a standards committee to “advise the organization on the creation of requirements for the first-ever accreditation programs addressing pharmacy benefits management in the Medicare, commercial insurance and health plan arenas”.
URAC has gotten into the managed care approval business in a big way of late, and now provides accreditation in 15 areas, including call center operations, consumer directed health, UR, workers comp UR, and claims processing. While the accreditation process can be onerous, some industry sources question the diligence, precision, and rigor of the process itself. According to one highly experienced workers comp clinical manager, the accreditation of one vendor was “shocking; I don’t know what they (URAC) were looking at…my audit clearly showed some major deficencies in (the vendor’s) QA, documentation, timeliness of communications, and feedback to the (clinical) staff.”
This echoes other comments I have heard from entities evaluating vendors; it appears that URAC certification/accreditation, which serves as a seal of approval, demonstrating the vendor has met rigorous standards, may be losing a bit of its “gold seal” status. This would be unfortunate, as many state regulators, employers, public entities, and vendors rely on URAC to be the expert in evaluating potential vendors for quality and consistency of operations.
What does this mean for you?
If URAC develops a PBM evaluation process that is rigorous, appropriate, and sensitive to both vendors’ and purchasers’ needs and requirements, your job should be easier. That doesn’t mean you shouldn’t do your own due diligence, and do it diligently.


Jun
1

Part D results are…

Part D’s enrollment deadline came and went, and along with it the orgy of claims, counter claims, blames and counter blames. So now that at least a bit of the dust has settled, where are we?
Confused.
Depending on whom you read or watch or listen to, the program has either been a success or a failure, is working or is not, is profitable or a loser, has enrolled “enough” people or has fallen well short.
The reality is as confusing as the perceptions appear to be. In any effort to cut through the spin, I checked in with Bob Laszewski of Health Policy and Strategy Associates. His take is it is too early to tell how things are going, and in the absence of truly meaningful metrics, we’re just going to have to wait and see.
Here’s why there is so much confusion.
There is no consensus on how many seniors have signed up for Part D or have alternate drug coverage under other plans. For starters, health plans and the Feds can’t agree on who is signed up by whom. Some health plans have been told they have thousands more members than they can account for, while others are being told large numbers of their “enrollees” actually signed up for Part D when they already had coverage under Medicare Advantage or another plan.
As near as I can figure it, there are between 8 million and 4.5 million seniors still without coverage. More details to follow…
Meanwhile, Humana, one of the more “successful” health plans in terms of signing up seniors for its Part D programs, recently saw its debt ratings outlook downgraded by AM Best from ‘stable” to “negative” in part due to large Part D enrollment and associated reliance on government contracts and increased capital requirements.
And AM Best may be on to something. The Medicare Trustees recently projected that the Part D program’s costs would increase by 11.5% annually over the next ten years. If those projections hold true, early claims about the currently “favorable” loss ratios may be short-lived.
We’ll have to wait until at least mid-July for reasonably accurate enrollment figures, and accurate financials will take another five months or so. If someone provides numbers in either category before those dates, be skeptical.


May
18

90% < 72%

CMS’ head Mark McClellan believes that over 90% of Medicare beneficiaries will have drug coverage after Monday’s deadline for Part D enrollment. That may be true, but that does NOT mean Part D enrollment is at 90%.
As has been ably reported in many places including this blog, before Part D most Medicare-eligible folks already had coverage from their Medicare Advantage plan, their employer, through their retirement plan, Tricare, or another source.
That left about 16 million without any drug coverage (out of the 43 million total eligibles). With the latest stats indicating there remain 4.5 million seniors without drug coverage, it looks like Part D will just pass the “adverse selection test” of a minimum of 70% of eligibles enrolled (my sense is a program of this type actually requires much higher enrollment, near 90%, to mitigate the risk of adverse selection).
Where does that leave us? There is a complex risk share program in place designed to protect Part D plan sponsors from adverse selection, a program that is in large part subsidized by taxpayers. However, there remains significant risk inherent in the program, a risk that private insurers would not have taken on without the taxpayers< backing them up.
So, we have a self-described conservative government using public funds and public policy to support private industry’s entrance into a new market.
Doesn’t sound very “conservative” to me. If Part D isn’t attractive enough for private companies to enter into on their own, why are we bribing them to do so? Are we not implicitly agreeing to commit public funds to this program? And if so, why didn’t we just cover drugs under Medicare, thereby avoiding all the doughnut hole, enrollment, dual-eligible and associated troubles?


May
12

Part D financials make no sense

A new study released by Part D advocacy group Medicare Today makes a compelling case for seniors’ enrollment in Part D. Authored by the Lewin Group (an excellent and unbiased health care reseach and analysis firm) the study makes a compelling case for seniors to enroll.
It makes an equally compelling case for adverse selection.
The only seniors who are signing up are those that can make money on the program. They make money because their premiums will be less than what they are spending on drugs today (or would be tomorrow). The Lewin report provides details on who benefits the most, what the average cost is ($37.43/month), and what benefits accrue to individuals with which conditions. It’s really well done.
Make no mistake; this is not insurance.
The Part D program is akin to an ATM card where you can withdraw any amount you want, as long as you pay a set minimum price. So, seniors, no dummies when it comes to managing money, can pretty quickly figure it out.
What’s missed in the discussion about Part D is the better off seniors are, the worse off taxpayers are. The ATM account has to be funded by someone, and that someone is the beleagured taxpayer.
This is nothing short of bizarre. The Feds are actively and aggressively encouraging enrollment in a program that will cost three-quarters of a trillion dollars over the next ten years, while cutting taxes that will be needed to pay for this program.
What does this mean for you?
Really high taxes in a few years. Followed by a taxpayer revolt. After which Congress will likely authorize the Feds to negotiate pricing with big pharma. Because the only other choice is to cut benefits, and seniors would never allow that.


Apr
25

Part D enrollment myths

Rather than do the ‘reinvent the wheel’ thing, I’ll just refer you to other folks who have been “fact checking” the Administration’s claims about the 30 million who have “signed up for” Medicare Part D.
The net is this – out of the 21.3 million eligibles (not covered under some other Medicare or other Rx program), a bit over one-third have signed up for stand-alone Part D.
Matt Holt replays a Wall Street Journal article that (finally!) breaks down the actual enrollment stats by source (something Kate Steadman, Matt, and I have been blogging on for months…).
This makes me nuts because it will be used by some to make the point that governmental approaches to health care coverage do not work. And in this case, they’ll be dead on.


Apr
19

Fiserv’s focus on work comp pharmacy

The workers comp drug management landscape is getting even more complicated, with new entities and renamed ones entering the space seemingly every day. One of the latest to hit the radar is Innoviant, a subsidiary of Fiserv.
Remember Fiserv owns Third Party Solutions as well as DirectCompRx, a third party biller and PBM respectively.
It appears that an Innoviant unit that specializes in marketing to injured workers and their attorneys, telling them that Innoviant will eliminate out of pocket costs and hassles, delivering drugs quickly via mail order etc. Sources on the payer side indicate that Innoviant then bills at rates above what is usually deemed appropriate, claiming that their requested reimbursement levels are reasonable.
Moreover, one payer in Florida has seen a recent and rather large influx of bills from the Innoviant mail order folks; this payer is concerned that TPS bills are finding themselves inserted into the “mail order” category, thereby circumventing existing processes for capturing these scripts and redirecting to network pharmacies.
Innoviant also goes so far as to recommend attorneys to those injured workers who are in need of a little legal assistance. One wonders if there is a quid pro quo here…
So, Fiserv owns a third party biller, PBM, and home delivery company (marketed to physicians and attorneys); it does appear that they are seeking to serve all masters, even competing ones.